ABCL Stock Forecast: AbCellera Biologics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$9.69
−7.45% on the day

The 14 Wall Street analysts covering AbCellera Biologics, Inc. hold a median 12-month price target of $18 — +85.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 78 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$3.4B
Ticker Nerd rank
78/ 100
Median analyst target
$18
Analysts covering
14
Revenue$4.0M−76.3% y/y
Operating income−$58.9M
Net income−$55.4M
Free cash flow$23.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.7%
1M
−17.3%
YTD
+183.3%
1Y
+184.2%
From 52W high
−34.6%
From 52W low
+248.6%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores AbCellera Biologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
78/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Growth
89
Revisions
77
Accruals
71
Value
55
Issuance
50
Quality
44
Volatility
29

Momentum (94): The shares have been drifting up relative to others.

Volatility (29): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ABCL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABCL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26ABCLHigh $30Median $18Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
13
Buy
1
Hold
0
Sell
$14
Low
$18
Median
$30
High

The green dot is the last close — the median target sits +85.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Nov 2026Piper SandlerMaintainsOverweight$12 → $20
11 Nov 2026StoneXMaintainsBuy$11 → $15
10 Nov 2026StifelMaintainsBuy$9.00 → $14
12 Oct 2026UBSInitiatesBuy$18
29 Sept 2026JP MorganInitiatesOverweight$17
24 Sept 2026Goldman SachsReinstatesNeutral$13
11 Aug 2026Truist SecuritiesMaintainsBuy$12 → $30
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$11 → $12
6 Aug 2026StifelMaintainsBuy$8.00 → $9.00
7 July 2026BenchmarkUpgradeBuy$11
5 May 2026Cantor FitzgeraldInitiatesOverweight—
10 Apr 2026Jones TradingInitiatesBuy—
7 Nov 2025Leerink PartnersDowngradeMarket Perform—
8 Aug 2025StifelMaintainsBuy—
14 July 2025KeybancMaintainsOverweight—
7 July 2025Leerink PartnersAssumesOutperform$5.00
16 May 2025Truist SecuritiesMaintainsBuy—
9 May 2025StifelMaintainsBuy—
16 Apr 2025KeybancMaintainsOverweight—
3 Mar 2025BenchmarkReiteratesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ABCL.

Market Radar

This page is one stock. Monday covers all of them.

ABCL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ABCL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, AbCellera Biologics, Inc. returned +184.2% against +6.9% for the S&P 500, dividends included.

ABCL vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Jan 26Apr 26Jul 26Oct 26ABCLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABCL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
48.1×

Cheaper than 5% of US stocks

Price / book
3.1×

Cheaper than 30% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−14.6%

Higher than 34% of US stocks

Return on assets
−8.8%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AbCellera Biologics, Inc. has a market value of $3.4B and an enterprise value of $2.8B.

  • Revenue in the twelve months to 30 June 2026: $66.2M. The latest quarter shrank 76.3% year on year.

  • Net income over the same four quarters: −$164.7M, a −248.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$119.7M.

  • Shares outstanding: 306.5M.

  • AbCellera Biologics, Inc. employs 562 people — $118K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ABCL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABCLAbCellera Biologics, Inc.$3.4B78
VKTXViking Therapeutics, Inc.$3.1B13
IOVAIovance Biotherapeutics, Inc.$3.1B95
ARQTArcutis Biotherapeutics, Inc.$3.3B69
VRDNViridian Therapeutics, Inc.$3.3B60
ELVNEnliven Therapeutics, Inc.$3.3B77
IRONDisc Medicine, Inc.$3.3B42

Take a look at ABCL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own AbCellera Biologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ABCL

What is the ABCL stock price forecast for 2026-2027?

The 14 Wall Street analysts covering AbCellera Biologics, Inc. have a median 12-month price target of $18, with estimates ranging from $14 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABCL stock a buy right now?

Of the 14 analysts covering AbCellera Biologics, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AbCellera Biologics, Inc. 78 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABCL?

As at 21 Nov 2026, AbCellera Biologics, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will ABCL stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +85.8% from the last close, and Ticker Nerd's factor model ranks AbCellera Biologics, Inc. 78 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABCL stock forecast for 2030?

No analyst covering AbCellera Biologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABCL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $30 over the next 12 months.

How has ABCL stock performed over the past year?

AbCellera Biologics, Inc. returned +184.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AbCellera Biologics, Inc. do?

AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines. Its platform combines biology, computation, engineering, and data science to identify rare and potent antibodies from natural immune responses and advance them into drug programs.

Company

About AbCellera Biologics, Inc.

AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines. Its platform combines biology, computation, engineering, and data science to identify rare and potent antibodies from natural immune responses and advance them into drug programs. The company’s current work spans endocrinology and women’s health, immunology, oncology, and inflammation-related diseases, reflecting a broad therapeutic focus. AbCellera Biologics Inc. also develops an internal pipeline of antibody candidates and collaborates with biopharmaceutical partners on discovery and development programs. Its capabilities extend from target identification and antibody discovery through clinical manufacturing support, making it an integrated player in the antibody therapeutics market.

CEO Dr. Carl L.G. Hansen Ph.D. · 562 employees · Canada · https://www.abcellera.com